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Available online 17 February 2016Biased ligands represent a new strategy for the development ofmore effective and better tolerated drugs. To date
there has been a paucity of research exploring the potential of ligands that exhibit either G protein or β-arrestin
pathway selectivity at the endothelin receptors. Re-analysis of datamay allow researchers to determinewhether
there is existing evidence that the endogenous ET peptides or currently available agonists and antagonists exhibit
pathway bias in a particular physiological or disease setting and this is explored in the review. An alternative to
molecules that bind at the orthosteric site of the ET receptors are cell penetrating peptides that interact with a
segment of an intracellular loop of the receptor to modify signalling behaviour. One such peptide IC2B has
been shown to have efﬁcacy in amodel of pulmonary arterial hypertension. Finally, understanding themolecular
pathways that contribute to disease is critical to determiningwhether biased ligandswill provide clinical beneﬁt.
The role of ETA signalling in ovarian cancer has been delineated in some detail and this has led to the suggestion
that the development of ETA G protein biased agonists or β-arrestin biased antagonists should be explored.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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IRL16201. Introduction
Our understanding of how ligands interact with G protein coupled
receptors is evolving, particularly the recognition that some have the
ability to preferentially activate a subset of intracellular signalling cas-
cades – so called pathway biased ligands [1]. Additionally, it is now ac-
cepted that recruitment of β-arrestin that occurs following activation
of the majority of GPCRs not only results in receptor desensitisation
and subsequent internalisation but may also contribute to cellular re-
sponses involved in normal physiology and disease such as cell migra-
tion and proliferation [2]. Therefore, exploiting ligand bias is likely to
lead to the development of more effective and better tolerated medi-
cines. This has so far beenmost clearly demonstrated for the μ opioid re-
ceptor where the agonist TRV130, a molecule that discriminates
between beneﬁcial analgesia and detrimental adverse effects such as re-
spiratory depression and nausea, exhibited an improved therapeutic
proﬁle compared to morphine in a randomized, double-blind,
placebo-controlled, crossover study in healthy volunteers [3]. Whereas
bias has been considered a property of synthetic ligands it has recently
been reported that for example endogenous opioids also show bias at
the μ-opioid receptor [4] indicating that the presence ofmultiple ligands
for a receptor, rather than simply representing physiological redundan-
cy, may allow for nuanced cell speciﬁc signalling. Distinct roles for theThis is an open access article under tthree endogenous endothelin (ET) peptides are emerging in develop-
ment and in, for example, ovarian physiology but whether pathway
bias may contribute to the physiology and pathophysiology of the en-
dogenous peptides in the ET system has not been explored. In contrast
the potential for targeting the endothelin receptors with synthetic bi-
ased ligands is starting to be considered. This brief review discusses cur-
rent research on biased signalling at the ET receptors and therapeutic
areas of interest.
2. ET receptors and probe dependence
Some of the pharmacology of the endothelin receptors has over the
last 20 years been described as atypical; not conforming to the basic te-
nets of receptor pharmacology. Particularly, this has been in differences
in the behaviour of the endogenous peptides and synthetic agonists
with respect to reversal by washout or blockade/reversal of responses
by antagonists in in vitro studies [5,6]. It is now apparent that for a par-
ticular receptor multiple active conformations, rather than just one, are
possible and ligands can stabilize different conformations of a receptor
that may activate subsets of available down-stream pathways. There-
fore, some of the atypical pharmacology reported for ET receptors may
be consistent with these agonists showing a degree of functional selec-
tivity, although differences in ligand-receptor kineticsmay also contrib-
ute to these observations. Additionally, because of the allosteric nature
of the interaction of ligand–GPCR–intracellular protein (e.g. G protein)
afﬁnity measured in binding assays may differ from afﬁnity measuredhe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Concentration response curves to ET-1 (●), ET-2 (■), ET-3 (▲) and S6b (▼) in
(A) the human endothelium-denuded saphenous vein and (B) an ETA-mediated β-
arrestin recruitment assay. Data are expressed as a percent of the maximum response of
ET-1 in each assay and data points are the mean ± s.e.m. of 3–13 experiments.
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receptor conformations then this allows the potential for orthosteric an-
tagonists to demonstrate agonist speciﬁc functional afﬁnities – consis-
tent with previously reported atypical pharmacology of probe
dependence [7].
3. Calculating ligandbias for the endogenous ETpeptides and related
sarafotoxin 6b at the ETA receptor
There has been at least one report in vitro that ET peptides exhibit
bias at the ETA receptor with ET-1 and ET-2 suggested to elicit their
long lasting constrictor responses via different mechanisms that was
also vascular bed dependent [8]. We have previously published data
on both the potency and efﬁcacy of endothelin peptides and
sarafotoxins as constrictors of human saphenous vein [9] and in β-
arrestin recruitment assays [10]. These data highlighted differences in
the relative potencies and efﬁcacies of these agonists in the ETAmediat-
ed constrictor and β-arrestin recruitment assays indicative of bias. Sev-
eral methods for determining pathway bias from such data have been
reported including determination of transducer coefﬁcients τ/KA, as de-
scribed by van Westhuizen and colleagues [11]. We have applied this
method to our existing data to determine whether the endogenous ET
peptides and related sarafotoxin 6b (S6b) show any evidence of bias
in the G protein dependent vasoconstrictor assay and G protein inde-
pendent β-arrestin recruitment assay. Determining bias requires desig-
nation of a reference compound that is preferably the endogenous
ligand. For the cardiovascular ETA receptor the most appropriate refer-
ence ligand is ET-1. All data are expressed as a % of the maximum ET-1
response and analysed as described [10], to obtain values of log10(τ/
KA) that are used for subsequent determination of bias factors. Fig. 1
shows that whilst ET-1, ET-2 and S6b are full agonists in the constrictor
assay (the ET-3 curve is incomplete at themaximum possible bath con-
centration) ET-3 and S6b are both partial agonists in the β-arrestin
assay.
Compared to ET-1, all agonists tested showed a 2–4 fold bias for the
G protein constrictor assay compared to the β-arrestin assay (Table 1).
This preliminary analysis indicated that at least modest pathway bias
for endogenous ET peptides is possible, however the physiologicalTable 1
Bias analysis for the relative effectiveness of endothelin peptides in the human saphenous vein
Saphenous vein constrictor assay β-Arrestin r
LogR ΔLogR RE LogR
ET-1 8.55 ± 0.15 0 ± 0.22 1 9.46 ± 0.08
ET-2 8.26 ± 0.21 −0.29 ± 0.26 0.51 8.67 ± 0.03
ET-3 6.80 ± 0.37 −1.75 ± 0.40 0.018 7.11 ± 0.03
S6b 8.11 ± 0.12 −0.44 ± 0.12 0.36 8.68 ± 0.06
R= (τ / KA), the transducer coefﬁcient, where τ is an index of agonist efﬁcacy and KA is function
reference agonist in a particular assay. ΔΔLogR is the relative ΔLogR values for particular agon
scribed by van der Westhuizen and colleagues [11].signiﬁcance of this, if any, requires more comprehensive analysis of
data for ET-1, ET-2 and ET-3 in a broader range of relevant pathway spe-
ciﬁc assays.
4. Ligand bias at the ETB receptor
There are currently no published data exploring biased agonism at
the ETB receptor. There are a number of ETB agonists available for
study including the endogenous peptide ET-3 and related sarafotoxin
6c (S6c) in addition to peptide agonists such as BQ3020 and IRL 1620.
IRL-1620 is of particular signiﬁcance as it is under investigation in a
number of therapeutic areas with efﬁcacy demonstrated in animal
models of stroke [12] and as an adjunct for improved delivery of chemo-
therapy targeting solid tumours [13]. It would therefore be of interest to
determine the relative effect of these agonists in a number of disease
relevant pathways,with comparison to ET-3 responses to determine ev-
idence of bias. These types of studies may highlight any differences be-
tween the agonists investigated that could be used either to further
understand the signalling of importance to disease progression or to re-
ﬁne clinical efﬁcacy of drugs by reducing on target detrimental effects
through deﬁned pathway activation.
5. Do ET receptor antagonists show pathway bias?
Of perhaps more consequence for the ET system is the possibility
that antagonists exhibit pathway bias. This has been reported for the
dual ETA/ETB antagonist bosentan. In human cloned receptors bosentan
exhibits a modest 20 fold selectivity for the ETA receptor [14] and in
human heart that expresses both receptor subtypes bosentan competes
for the binding of [125I]ET-1with a single afﬁnity (KD: 78 nM) indicating
that it does not distinguish between the native receptors in this tissue
[15]. In human blood vessels that express predominantly ETA receptors
bosentan exhibited, as expected, 2–20 fold higher afﬁnity than in heart
with KD of 32 nM in saphenous vein [16] and 3 nM in coronary artery
[17]. In contrast bosentan was a much less effective antagonist than
would be predicted from its binding afﬁnity in both ETA mediated vaso-
constriction in human saphenous vein and coronary artery [15], in ETB
mediated smooth muscle contraction [14] and ETB β-arrestin recruit-
ment experiments [10] with a functional afﬁnity of about 2 μM in all
these assays. Unexpectedly, in the ETA mediated β-arrestin assay
bosentan was 200 fold more effective an antagonist with KB of 10 nM
[10] suggesting that bosentan is an ETA β-arrestin biased antagonist. It
is interesting to speculate that the relative effectiveness of bosentan in
treatment of pulmonary arterial hypertension compared to its generally
low potency as an antagonist in vitro may in part be explained by the
greater antagonism of detrimental ETA linked β-arrestin mediated
ERK1/2 signalling [18] that could contribute to smooth muscle cell pro-
liferation in this disease.
6. Alternative strategies: cell penetrating peptides as biased
antagonists
Cell penetrating peptides (CPPs) are a superfamily of peptides that
interact with an intracellular segment of a G protein coupled receptorconstrictor and ETA-mediated β-arrestin recruitment assays.
ecruitment assay Saphenous vein vs β-arrestin
ΔLogR RE ΔΔLogR Bias factor
0 ± 0.11 1 0 ± 0.24 1
−0.79 ± 0.08 0.16 0.49 ± 0.27 3.1
−2.35 ± 0.08 0.0045 0.60 ± 0.41 4.0
−0.78 ± 0.10 0.17 0.34 ± 0.15 2.2
al afﬁnity of the agonist.ΔLogR is the relative LogR values of test agonists compared to the
ists between assays. The bias factor is determined as 10ΔΔLogR. Analysis performed as de-
Fig. 2. Proposed role for ET-1 activation of ETA receptors in ovarian cancer (modiﬁed from [24]) and potential beneﬁcial effects of either a Gαs biased agonist orβ-arrestin biased antagonist.
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developed for over 20 GPCRs including proteinase activated (PAR1,
PAR2 and PAR4) and chemokine (CXCR1, CXCR2 and CXCR4) receptors.
There has been one report of a CPP, IC2B, targeting the second intracel-
lular loop of the ETB receptor which has been shown to attenuate pul-
monary Akt and ERK signalling and to blunt the development of
hypoxic pulmonary hypertension in a rat in vivo model [20] that is
thought to contribute to disease progression.Whatwasmost interesting
is that blockade of the ETB receptor has previously been reported to en-
hance development of pulmonary arterial hypertension in rodents sug-
gesting that in the study by Green and colleagues [20] IC2B may be
selectively targeting those ETB pathways contributing to muscularisation
of the pulmonary arterial smooth muscle. This would leave unopposed
beneﬁcial ETB receptor functions such as release of endothelial derived
dilators, although this is yet to be conﬁrmed.
7. Clinical potential of ET receptor biased ligands
Is there a clinical need for ET receptor biased ligands? Evidence is
strongest from research in epithelial ovarian cancer demonstrating
that ET-1 stimulated ETA-mediated β-arrestin signalling leads to activa-
tion of the oncogenic mediator NF-κB [21] and that β-arrestin-1 epige-
netically regulates ET-1-induced β-catenin signalling [22,23] both
contributing to tumour cell proliferation, invasion and metastasis. A β-
arrestin biased ETA antagonist would be predicted to have beneﬁt over
a non-biased ETA antagonist in ovarian cancer as ETA/Gαs/cAMP activa-
tion of protein kinase A opposes the detrimental ETA/β-arrestin stimu-
lated expression of cancer genes. ETA/Gq signalling is also oncogenic
therefore an alternative strategy that may demonstrate even greater
target reﬁnement would be to develop an ETA/Gαs biased agonist as
proposed by Teoh and colleagues [24] (Fig. 2). Interestingly, pepducins
have been designed for the β2-adrenoreceptor that selectively pro-
mote a Gαs biased conformation [25] therefore this may be one
strategy that can be applied to biased targeting of the ETA receptor
in cancer.
Could selective activation or inhibition of ET signalling pathways in
heart failure result in clinically efﬁcacious drugs and explain the lack
of beneﬁt of endothelin receptor antagonists in heart failure clinical tri-
als to date, despite promising evidence from pre-clinical studies? For
the angiotensin-II system it has been demonstrated that β-arrestin me-
diated signalling in heart failure is beneﬁcial and selective activation ofthis pathway using TRV027 (and thus inhibition of G-protein signalling)
promotes both vasodilatation and improved cardiac function at least in
animal models [26]. This compound is currently being investigated in a
Phase IIb study in patients hospitalised for acute decompensated heart
failure (ClinialTrials.gov identiﬁer NCT01966601) with estimated com-
pletion March 2016. Conversely, β-arrestin signalling in cardiac ﬁbro-
blasts has been proposed to contribute to detrimental ventricular
remodelling [27]. It is not known if ET receptor mediated β-arrestin sig-
nalling is protective in heart failure, but if so it could be inferred that
currently available endothelin antagonists that block G-protein and β-
arrestin signalling or bosentan that may be a β-arrestin biased antago-
nist would not produce clinical beneﬁt and may even be detrimental.
However, the lack of efﬁcacy in heart failure trials was predominantly
owing to the development of peripheral oedema, thought to be a result
of effects on endothelin mediated renal salt and water homeostasis
rather than a lack of beneﬁcial effect on haemodynamics [28]. It has
also been suggested that the contribution of increased ET-1 to patholog-
ical cardiac remodelling in heart failure may be a result of ETA mediated
inhibition of reuptake of noradrenaline released from cardiac sympa-
thetic nerves [29]. Consequently endothelin antagonists would not con-
fer additional advantage in patients already taking β-blockers enrolled
in these trials. Whether the beneﬁcial and detrimental actions of
endothelin antagonists in heart failure or other conditions such as hy-
pertension could be discerned by the development of ligands with a
particular signalling proﬁle remains mere speculation at this time but
should be investigated as the ﬁeld matures.
In summary, compared to the development and exploitation of bi-
ased ligands for other GPCRs the identiﬁcation of compounds that selec-
tively engage or block a subset of ET receptor activated signalling is only
now beginning to be explored. However, the possibility that the endog-
enous ET peptides and currently available agonists and antagonists may
show pathway bias should be considered and investigated by all those
with an interest in the role of the endothelin system in health and
disease.Acknowledgements
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